Literature DB >> 3979520

Pulmonary toxicity of cyclophosphamide: a 1-year study.

C C Morse, C Sigler, S Lock, P J Hakkinen, W M Haschek, H P Witschi.   

Abstract

The development of cyclophosphamide-induced pulmonary lesions over a 1-year period was studied in mice. Male BALB/c mice received a single intraperitoneal injection of 100 mg/kg of cyclophosphamide. Within 3 weeks there were scattered foci of intraalveolar foamy macrophages. With time, these foci increased in size and, 1 year later, occupied large areas in all lung lobes. There was also diffuse interstitial fibrosis. Chemical determination done 3, 12, 24, and 52 weeks after cyclophosphamide showed that lungs of animals treated with cyclophosphamide had significantly more hydroxyproline per lung than controls. One year after cyclophosphamide pressure-volume curves measured in vivo were shifted down and to the right and total lung volumes were decreased. A single injection of cyclophosphamide produced an irreversible and progressive pulmonary lesion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3979520     DOI: 10.1016/0014-4800(85)90031-0

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  3 in total

1.  The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide.

Authors:  A Panoskaltsis-Mortari; P A Taylor; T M Yaeger; O D Wangensteen; P B Bitterman; D H Ingbar; D A Vallera; B R Blazar
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Type 2 pneumocyte responses to cyclophosphamide-induced pulmonary injury: functional and morphological correlation.

Authors:  R K Kumar; J Y Truscott; G C Rhodes; A W Lykke
Journal:  Br J Exp Pathol       Date:  1988-02

3.  Responses of the lung to toxic injury.

Authors:  H Witschi
Journal:  Environ Health Perspect       Date:  1990-04       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.